Here’s a breakdown of the key data from the provided text, focusing on the two drugs discussed:
1.enlicitide Decanoate (for Cholesterol Management)
* What it is: An oral, once-daily pill.
* How it works: Reduces LDL-C (bad cholesterol).
* trial Results (CORALreef):
* LDL-C reductions observed as early as week 4.
* At 1 year, important LDL-C reduction of 61.5% compared to placebo (P < .001).
* Potential impact: Could transform cholesterol management if approved by the FDA.
2. Sacituzumab tirumotecan (Sac-TMT) (for Lung Cancer)
* What it is: An antibody-drug conjugate targeting TROP2.
* Target Condition: Previously treated advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutations.
* Trial Results (optitrop-Lung04):
* improved progression-free survival (PFS) and overall survival (OS) compared to platinum-based chemotherapy.
* PFS: Median of 8.3 months with Sac-TMT vs. 4.3 months with chemotherapy (HR 0.49; 95% CI, 0.39-0.62).
* OS: Considerably longer with Sac-TMT (HR 0.60; 95% CI,0.44-0.82; P = .001).
* Regulatory Status:
* Breakthrough Therapy Designation from the FDA.
* National Priority Voucher awarded.
* Potential Impact: Could address a significant unmet need for patients with EGFR-mutated NSCLC who have limited treatment options.
Critically important Note: The dates in the references (December 19, 2025, January 7, 2026, November 19, 2025) suggest this information is from a future publication or press release.
